These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29570771)

  • 1. The non-biphenyl-tetrazole angiotensin AT
    Takezako T; Unal H; Karnik SS; Node K
    Br J Pharmacol; 2018 Jun; 175(12):2454-2469. PubMed ID: 29570771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery.
    Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
    J Cardiovasc Pharmacol; 2002 Jul; 40(1):50-7. PubMed ID: 12072577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
    Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Hypertens; 2001 Dec; 19(12):2241-50. PubMed ID: 11725169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
    Muders F; Palkovits M; Bahner U; Kirst I; Elsner D; Jandeleit-Dahm K
    Pharmacol Res; 2001 Mar; 43(3):251-5. PubMed ID: 11401417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutively active mutant N111G of angiotensin II type 1 (AT(1)) receptor induces homologous internalization through mediation of AT(1)-receptor antagonist.
    Bhuiyan MA; Hossain M; Miura S; Nakamura T; Ozaki M; Nagatomo T
    J Pharmacol Sci; 2009 Nov; 111(3):227-34. PubMed ID: 19881223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan.
    Nap A; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    Eur J Pharmacol; 2003 May; 469(1-3):117-24. PubMed ID: 12782193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.
    Miura S; Kiya Y; Kanazawa T; Imaizumi S; Fujino M; Matsuo Y; Karnik SS; Saku K
    Mol Endocrinol; 2008 Jan; 22(1):139-46. PubMed ID: 17901125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of homologous internalization of constitutively active N111G mutant of AT(1) receptor.
    Bhuiyan MA; Nagatomo T
    Methods Enzymol; 2010; 484():165-77. PubMed ID: 21036232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different prejunctional and postjunctional responses to angiotensin II and AT1-receptor inhibition: influence of maturation.
    Nap A; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):432-9. PubMed ID: 15076228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
    Hedner T
    J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation.
    Qin Y; Yasuda N; Akazawa H; Ito K; Kudo Y; Liao CH; Yamamoto R; Miura S; Saku K; Komuro I
    Hypertens Res; 2009 Oct; 32(10):875-83. PubMed ID: 19662020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical profile of the angiotensin II receptor blocker eprosartan.
    Hedner T
    J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
    Blankestijn PJ; Rupp H
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The constitutively active N111G-AT1 receptor for angiotensin II modifies the morphology and cytoskeletal organization of HEK-293 cells.
    Auger-Messier M; Turgeon ES; Leduc R; Escher E; Guillemette G
    Exp Cell Res; 2005 Aug; 308(1):188-95. PubMed ID: 15896777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
    Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
    Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
    Heusser K; Vitkovsky J; Schmieder RE; Schobel HP
    Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selenosartans: novel selenophene analogues of milfasartan and eprosartan.
    Grange RL; Ziogas J; North AJ; Angus JA; Schiesser CH
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1241-4. PubMed ID: 18191398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.